Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Looking forward:

With the data for M281 and M254 not due out until 2020, the only obvious near-term events for Momenta are finding a partner for M923 and a resolution of its partnership with Mylan. There's also the possibility of out-licensing M281 and M254, but Momenta would be able to get a better price if it waits until it generates the data, so a secondary offering may end up being the best choice for shareholders even though it'll result in some dilution.

Momenta Moves On
Brian Orelli (TMFBiologyFool)
Nov 16, 2018

Read more:
https://www.fool.com/investing/2018/11/16/momenta-moves-on.aspx